Vontobel Holding Ltd. bought a new position in GoodRx Holdings, Inc. (NASDAQ:GDRX – Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 11,716 shares of the company’s stock, valued at approximately $58,000.
Other hedge funds and other institutional investors have also made changes to their positions in the company. 8 Knots Management LLC purchased a new position in shares of GoodRx in the first quarter worth approximately $8,106,000. EVR Research LP increased its position in shares of GoodRx by 243.3% in the first quarter. EVR Research LP now owns 1,300,000 shares of the company’s stock worth $5,733,000 after acquiring an additional 921,337 shares in the last quarter. PDT Partners LLC increased its position in shares of GoodRx by 1,351.3% in the first quarter. PDT Partners LLC now owns 370,219 shares of the company’s stock worth $1,633,000 after acquiring an additional 344,709 shares in the last quarter. Raymond James Financial Inc. increased its position in shares of GoodRx by 54.6% in the first quarter. Raymond James Financial Inc. now owns 830,950 shares of the company’s stock worth $3,664,000 after acquiring an additional 293,420 shares in the last quarter. Finally, Algert Global LLC purchased a new position in shares of GoodRx in the first quarter worth approximately $1,224,000. 63.77% of the stock is currently owned by institutional investors.
GoodRx Stock Performance
GDRX stock opened at $4.02 on Thursday. The company has a quick ratio of 4.21, a current ratio of 4.21 and a debt-to-equity ratio of 0.75. The company has a market capitalization of $1.40 billion, a price-to-earnings ratio of 40.20, a P/E/G ratio of 1.80 and a beta of 1.23. GoodRx Holdings, Inc. has a 12 month low of $3.31 and a 12 month high of $7.11. The firm has a 50 day moving average of $4.20 and a two-hundred day moving average of $4.37.
Insider Buying and Selling at GoodRx
In other news, major shareholder Equity Vii L.P. Spectrum sold 16,016 shares of the business’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $4.05, for a total value of $64,864.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.53% of the company’s stock.
Wall Street Analyst Weigh In
GDRX has been the topic of several analyst reports. Weiss Ratings reissued a “hold (c-)” rating on shares of GoodRx in a research report on Wednesday, October 8th. Raymond James Financial downgraded shares of GoodRx from a “strong-buy” rating to an “outperform” rating in a research report on Friday, August 8th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $6.00 target price on shares of GoodRx in a research report on Monday, August 11th. Five equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $5.80.
Read Our Latest Analysis on GoodRx
GoodRx Profile
GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.
Featured Articles
- Five stocks we like better than GoodRx
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- What is a Secondary Public Offering? What Investors Need to Know
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- Best Aerospace Stocks Investing
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Want to see what other hedge funds are holding GDRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GoodRx Holdings, Inc. (NASDAQ:GDRX – Free Report).
Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.